Week In Review: Curon Bio Acquires Rights To Lymphoma Drug In $150 Million Deal
October 17, 2020 at 14:14 PM EDT
Curon Biopharma, a Shanghai clinical-stage in-licensing company, acquired China rights to Tenalisib, a dual PI3K delta and gamma inhibitor, from Rhizen Pharma. Rhizen will receive milestone payments worth up to $149.5 million, plus royalties.